Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their target price on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th.

Minerva Neurosciences Stock Down 0.8 %

Shares of NASDAQ:NERV opened at $2.44 on Friday. The firm has a 50-day simple moving average of $2.68 and a 200 day simple moving average of $2.80. Minerva Neurosciences has a fifty-two week low of $2.26 and a fifty-two week high of $13.49. The company has a market cap of $17.05 million, a PE ratio of -0.55 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). As a group, research analysts forecast that Minerva Neurosciences will post -2.26 EPS for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.